Mark Schoenberg Sells 5,222 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 5,222 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the sale, the insider directly owned 139,763 shares in the company, valued at approximately $3,815,529.90. The trade was a 3.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Urogen Pharma Stock Performance

URGN stock traded up $0.33 during midday trading on Tuesday, reaching $27.58. 434,080 shares of the company were exchanged, compared to its average volume of 799,607. The stock’s 50-day simple moving average is $24.84 and its 200 day simple moving average is $22.75. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -10.03 and a beta of 1.59. Urogen Pharma has a 1-year low of $6.73 and a 1-year high of $32.37.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. On average, research analysts anticipate that Urogen Pharma will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on URGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Urogen Pharma in a report on Wednesday, June 3rd. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.67.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after purchasing an additional 1,653 shares in the last quarter. Main Street Financial Solutions LLC boosted its position in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after purchasing an additional 1,968 shares in the last quarter. Barclays PLC boosted its position in shares of Urogen Pharma by 3.8% during the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,125 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its position in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.